Entry Point Capital, LLC Madrigal Pharmaceuticals, Inc. Transaction History
Entry Point Capital, LLC
- $112 Billion
- Q1 2024
A detailed history of Entry Point Capital, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 155 shares of MDGL stock, worth $43,717. This represents 0.04% of its overall portfolio holdings.
Number of Shares
155Holding current value
$43,717% of portfolio
0.04%Shares
1 transactions
Others Institutions Holding MDGL
# of Institutions
313Shares Held
20MCall Options Held
824KPut Options Held
1.04M-
Janus Henderson Group PLC London, X02.6MShares$734 Million0.39% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$556 Million6.66% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.94MShares$548 Million6.26% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny1.78MShares$501 Million34.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.67MShares$471 Million0.01% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $4.82B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...